INDPHealthcare · BiotechnologyINDP Stock Forecast: Indaptus Therapeutics, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 8 Aug 2026 — in the lower half.
INDP stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Indaptus Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (73): Smaller than most of the companies we track.
Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Indaptus Therapeutics, Inc. — and when they’d sell — is the membership.
INDP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on INDP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Nov 2024 | Maxim Group | Maintains | Buy | $8.00 → $5.00 |
| 16 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Mar 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Mar 2023 | HC Wainwright & Co. | Reiterates | Overweight | — |
| 8 Feb 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Jan 2022 | HC Wainwright & Co. | Assumes | Buy | $15 |
| 19 Oct 2021 | Maxim Group | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
INDP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Indaptus Therapeutics, Inc. (INDP) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.1×
- Price / sales
- —
- Price / book
- 107.3×
- EV / EBITDA
- −6.7×
Cheaper than 76% of US stocks
Cheaper than 1% of US stocks
Cheaper than 81% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 33% of US stocks
Higher than 30% of US stocks
- Return on equity
- −931.8%
- Return on assets
- −286.8%
- Dividend yield
- —
Higher than 1% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
INDP vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INDP appears on the weeks it earns a place.
Frequently asked questions about INDP stock
Is INDP stock a buy right now?
Of the 1 analysts covering Indaptus Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Indaptus Therapeutics, Inc. 26 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank INDP?
As at 8 Aug 2026, Indaptus Therapeutics, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (73 of 100).
What is the INDP stock forecast for 2030?
No analyst covering Indaptus Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INDP are extrapolating price history, which says nothing about the business.
How has INDP stock performed over the past year?
Indaptus Therapeutics, Inc. returned -82.3% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Indaptus Therapeutics, Inc. do?
Indaptus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing systemically administered immunotherapies for cancer and chronic viral infections.
About Indaptus Therapeutics, Inc.
Indaptus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing systemically administered immunotherapies for cancer and chronic viral infections. The company’s core platform leverages proprietary, attenuated, killed, non-pathogenic Gram-negative bacteria engineered to reduce intravenous toxicity while preserving the ability to activate both innate and adaptive immune responses. This approach is designed to deliver a multi-targeted package of immune-stimulating signals that can be given safely via intravenous infusion, aiming to trigger broad anti-tumor and anti-viral activity. Indaptus Therapeutics’ lead candidate, Decoy20, is being developed for solid tumors such as colorectal, hepatocellular, and pancreatic cancers, as well as non-Hodgkin’s lymphoma, and is also being explored in settings related to chronic viral infections including hepatitis B and HIV. Operating within the healthcare and biotechnology sector, and headquartered in New York, New York, the company occupies a niche in the immuno-oncology and immuno-virology landscape, targeting indications where durable immune-driven responses are a key clinical objective.
CEO Mr. Junyi Dai · 5 employees · United States · https://indaptusrx.com